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EDITORIAL
A Different Type of Procedure for a Different Type of Pain
Michael C. Hsu and Daniel J. Clauw
In a randomized, placebo-controlled trial de-
scribed in this issue of Arthritis & Rheumatism, Fregni
and colleagues studied the effect of transcranial direct
current stimulation (tDCS) on pain and quality of life in
patients with fibromyalgia (1). These investigators ob-
served that this noninvasive approach was safe and
effective for the short-term treatment of fibromyalgia-
associated pain. The study also highlights the rapid
movement toward neuromodulatory treatment of
chronic pain, which requires a paradigm shift in how we
think of chronic pain and its management.
The use of various procedures to treat pain is
certainly nothing new. For centuries, many procedures
have been performed to ameliorate the “source” of pain
and typically have been aimed at eliminating peripheral
inflammation or repairing peripheral tissue. Some of
these procedures work well (e.g., hip replacement sur-
gery), while others have widespread use even though
they have not been shown to be efficacious when for-
mally tested in randomized controlled trials. For exam-
ple, recent systematic reviews revealed only limited
evidence, if any, for the long-term therapeutic benefits
(compared with placebo) of facet joint injections, extra-
corporeal shock wave therapy for lateral elbow pain, or
corticosteroid injections for shoulder capsulitis, rotator
cuff tendonitis, and lateral epicondylitis (2–5). More-
over, procedures aimed at stabilizing or fusing vertebrae
or joints have shown limited success in treating pain, and
only in highly selected patients (6,7).
The failure of peripherally directed procedures to
treat many types of pain is consonant with our current
understanding that not all chronic pain is attributable to
peripheral damage or inflammation, as measured, for
instance, radiographically. In patients with osteoarthri-
tis, there is little relationship between the degree of joint
space narrowing and the degree of pain (8). In the
setting of low back pain, structural abnormalities on
magnetic resonance imaging and discography have only
a weak association with back pain episodes and no
association with disability or future medical care (9). In
fact, in nearly any disease there is a poor relationship
between an individual patient’s level of pain and the
extent or degree of peripheral damage or inflammation
that can be documented on objective testing.
We are beginning to understand why such dis-
crepancies may occur. In addition to peripheral or
nociceptive pain due to damage or inflammation, there
are (at least) 2 other mechanistically distinct types of
chronic pain, and these may coexist with peripheral pain
(10).
Neuropathic pain is a non-nociceptive chronic
pain that has been recognized and understood for some
time. Although neuropathic pain is usually attributed to
damage and subsequent irritability of peripheral nerves,
central changes in pain processing constitute a second
type of chronic pain in patients with this condition (11).
A third type of chronic pain is caused by distur-
bances in the central processing of pain, alone rather
than in association with identifiable peripheral input or
nerve damage. Such conditions have sometimes been
included in the category of neuropathic pain, but they
have fundamental differences from neuropathic pain
and are often termed “central” pain syndromes. Such
syndromes include fibromyalgia, irritable bowel syn-
drome, temporomandibular joint disorder, and idio-
pathic low back pain (12). The hallmark of these condi-
tions is the evidence of pain amplification occurring in
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the central nervous system, manifest as allodynia (pain
in response to normally nonpainful stimuli) and/or hy-
peralgesia (increased pain in response to normally pain-
ful stimuli) on physical examination, that can be corrob-
orated and “objectified” using sensory testing and
functional neuroimaging. This pain amplification may be
accompanied by psychological factors but can clearly
occur independently and is neurobiologically distinct
from depression and/or anxiety (13).
We are also beginning to understand the mech-
anisms behind this “increased gain” in pain and sensory
processing systems. For rheumatologists, it is simplest to
think of pain and sensory processing systems as being
analogous to the immune system. Autoimmune or in-
flammatory disorders occur because of a regional or
systemic imbalance of proinflammatory versus antiin-
flammatory influences. Similarly, many inhibitory and
facilitatory influences on pain processing can act either
regionally (at the level of the peripheral nerve or spinal
cord) or systemically (at the level of the spinal cord or
brain). For example, pain in patients with fibromyalgia
might be attributable, in part, to a lack of normal
antinociceptive mechanisms, such as a defect in the
function of descending inhibitory (analgesic) pathways,
and also a possible increase in spinal excitatory activity
such as that which occurs in wind-up or central sensiti-
zation (14,15). The ultimate proof that these defective
central control mechanisms are playing a role in central
pain states comes from randomized clinical trials dem-
onstrating that neuroactive compounds that either in-
crease inhibitory activity (e.g., serotonin–norepinephrine
reuptake inhibitors) or decrease facilitatory activity
(e.g., antiepileptics) can be efficacious in the treatment
of fibromyalgia as well as neuropathic pain (16,17).
The report by Fregni and colleagues raises the
possibility that we may also be able to reduce pain in
patients with these central pain states by transcutane-
ously electrically stimulating the brain regions that di-
rectly or indirectly influence pain processing. In this
study, 32 female patients with fibromyalgia were ran-
domized into 3 groups: tDCS of the primary motor
cortex (M1), tDCS of the dorsolateral prefrontal cortex
(DLPFC), and sham stimulation. Patients in the 2
active-treatment arms received a constant 2-mA current,
20 minutes daily for 5 consecutive days, while patients in
the sham group received only 30 seconds of stimulation
of M1 each day. Fregni et al observed a significant
decrease in pain (as measured by visual analog scale,
clinician’s global assessment, and patient’s global assess-
ment) in the M1 group compared with the sham group.
In contrast, patients in the DLPFC group, who received
the same magnitude of electrical stimulation but in a
different brain region, had no clinical improvement,
making it much less likely that the observed effect in the
M1 group was a placebo effect. Pain reduction in the M1
group continued through the 21-day followup period,
and no significant side effects were associated with tDCS
compared with sham treatment.
In a separate study, these investigators also ob-
served that tDCS had analgesic properties for the cen-
tral pain of spinal cord injury (18). A similar treatment,
transcranial magnetic stimulation (TMS), has been more
widely studied and used to stimulate neural regions
noninvasively and has analgesic properties in both
healthy individuals and patients with chronic pain (19).
The mechanisms by which these treatments work are not
yet precisely understood, but presumably these treat-
ments are either stimulating inhibitory pathways, such as
known endogenous analgesic pathways, or reducing fa-
cilitatory activity.
The results of this study, if confirmed by other
investigators, suggest an alternative mode of therapy for
patients with fibromyalgia or other central pain syn-
dromes. Other neurostimulatory therapies, such as deep
brain stimulation (20), spinal cord stimulation (21), and
vagus nerve stimulation (22), have also shown promising
efficacy in decreasing pain and improving quality of life
in selected groups of patients with chronic pain. Al-
though implantable neurostimulatory devices are asso-
ciated with the inherent risk of complications such as
(implant-site) infection and hardware failure, tDCS and
TMS have the advantage of being both noninvasive and
easily transferable between sites and may obviate the
need for invasive neuromodulatory procedures. At a
minimum, these techniques will help in the selection of
appropriate candidates and appropriate sites for implan-
tation of neurostimulatory devices.
It will take some time before we determine the
precise role for these types of therapy in patients with
fibromyalgia. In the meantime, the study by Fregni et al
provides further evidence that fibromyalgia is associated
with abnormal neural activity, and that therapy directed
toward these underlying mechanisms can have a specific
and clinically meaningful effect on symptoms.
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